What the company does
DreamCIS is a contract research organization (CRO), a company that handles clinical trials on behalf of pharmaceutical firms that want to reduce the cost and complexity of developing new drugs.
It provides services such as trial design, consulting, monitoring, data management, and regulatory filing support to drug developers. Listed on KOSDAQ, South Korea's tech and small-cap stock exchange, it manages the full outsourced research process from early trial planning through to post-market surveillance studies.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$48.3M
▲ +13.6% YoY
Operating profit · FY2025
US$3.8M
▲ +3.6% YoY
Net income · FY2025
US$5.4M
▲ +38.7% YoY
Revenue
- FY2023US$34.7M
- FY2024US$42.5M
- FY2025US$48.3M
Operating profit
- FY2023US$1.2M
- FY2024US$3.7M
- FY2025US$3.8M
Net income
- FY2023US$2.8M
- FY2024US$3.9M
- FY2025US$5.4M
Key ratios (FY2025)
ROE
8.8%
Debt/Eq
88.6%
Op. margin
7.9%
Net margin
11.3%
Rev. YoY
▲ +13.6%
Price charts coming soon
Interactive price history isn't here yet. Would you use it?